BioMarin Pharmaceutical, a Dublin, Ireland-based bio/pharmaceutical company, has agreed to acquire Amicus Therapeutics, a Princeton, New Jersey-based bio/pharmaceutical company specializing in rare diseases, for $4.8 billion. 

The acquisition will add two new treatments to BioMarin’s existing portfolio of medicines that target lysosomal storage disorders: Galafold (migalastat), an oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), a two-component therapy for Pompe disease. Amicus also has US rights to DMX-200, an investigational small-molecule drug for the treatment of focal segmental glomerulosclerosis, a rare kidney disease, in Phase III development.  

Under the agreement, BioMarin will acquire Amicus for $14.50 per share in an all-cash transaction, for a total value of $4.8 billion. The deal has been unanimously approved by the Boards of Directors of both companies and Amicus’ Board of Directors unanimously recommended that Amicus’ stockholders vote to adopt the agreement. The transaction is expected to close in the second quarter of 2026, subject to regulatory clearances, approval by the stockholders of Amicus, and other customary closing conditions. 

Separately, Amicus has resolved the patent litigation it brought in response to Aurobindo Pharma’s and Lupin Ltd.’s abbreviated new drug applications seeking approval to market a generic version of Galafold 123-mg capsules prior to expiration of certain Amicus patents. Galafold is Amicus’ top-selling product with 2024 revenues of $458 million and revenues of $371 million for the first nine months of 2025.   

Amicus has entered into license agreements with Aurobindo and Lupin for Galafold 123-mg capsules under which Amicus will grant Aurobindo and Lupin licenses to market generic versions of Galafold in the US beginning on January 30, 2037, if approved by the US Food and Drug Administration (FDA). The companies will submit the confidential license agreements to the US Federal Trade Commission and the US Department of Justice for review. Also, the companies will terminate all ongoing Hatch-Waxman litigation between Amicus and Aurobindo and Lupin regarding Galafold patents pending in a US federal district court (U.S. District Court for the District of Delaware).  

Source: BioMarin Pharmaceutical